Long-term use of low-dose aspirin may lower PCa mortality


Long-term use of low-dose aspirin following a diagnosis of prostate cancer may decrease the risk of dying from the disease

Aspirin has shown to be effective in the prevention of some tumors like Colon and prostate. Moreover, Recent studies suggest that aspirin use may improve survival in patients with prostate cancer. The objective of this study was to assess the association between postdiagnosis use of low-dose aspirin and prostate cancer mortality.

In a nationwide cohort study of 29,136 patients diagnosed with PCa in Denmark, Charlotte Skriver, MSc, of the Danish Cancer Society Research Center in Copenhagen, and colleagues found no effect of low-dose aspirin use assessed within 1 year after diagnosis on PCa mortality in adjusted analyses, according to study findings published in the Annals of Internal Medicine. Low-dose aspirin use was associated with a significant 12% increased risk of other-cause mortality.

After exposure periods of 5 and 7.5 years after diagnosis, however, low-dose aspirin use was associated with 9% and 18% decreased risks of PCa mortality, respectively, during follow-up (which began 5 and 7.5 years after PCa diagnosis, respectively).

During the 7.5 year exposure period, low-dose aspirin use for at least 1096 days (more than 3 years) and cumulative use of at least 1096 tablets (equivalent to more than 3 years of use assuming a dosage of 1 tablet per day) were associated with a significant 21% and 23% decreased risk of PCa mortality, respectively, compared with nonuse.

The study did not support an overall effect of postdiagnosis low-dose aspirin use on prostate cancer mortality. However, results for extended exposure periods suggest that low-dose aspirin use might be inversely associated with prostate cancer mortality after 5 years from cancer diagnosis.


Skriver C, Dehlendorff C, Borre M, et al. Use of low-dose aspirin and mortality after prostate cancer diagnosis: A nationwide cohort study. Ann Intern Med. 2019; published online ahead of print. DOI: 10.7326/M17-3085